Autopsy report · NCT05272813

A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

“The study is terminated due to major protocol revisions.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 7 months before it stopped.
• 13 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Sponsor type

Industry

Conditions

Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Interventions

MS-553

Participants

13

Sites

1

Countries

China

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.